Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01445769 · ClinicalTrials.gov registry record · Phase 2
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT01445769 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 45 participants.
The verdict
NCT01445769, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the effect of an alternative dosing strategy of ruxolitinib in subjects with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) and post essential thrombocythemia-myelofibrosis (PET-MF) in order to minimize the development of anemia and thrombocytopenia.
Interventions
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01445769
The ClinicalTrials.gov registry entry for NCT01445769 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT01445769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01445769 about?
NCT01445769 is a clinical study titled "Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis". The purpose of this study was to evaluate the effect of an alternative dosing strategy of ruxolitinib in subjects with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) and post essential thrombocythemia-myelofibrosis (PET-MF) in order to minimize the development of anemia a...
What is the current status of trial NCT01445769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2011-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01445769?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT01445769?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.